Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Abbott Laboratories (ABT)
NYSE:ABT
Holding ABT?
Track your performance easily
ABT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$99.71 - $121.64
Previous Close$117.26
Volume272.49K
Average Volume (3M)4.96M
Market Cap
$203.04B
Enterprise Value$210.81B
Total Cash (Recent Filing)$7.79B
Total Debt (Recent Filing)$14.98B
Price to Earnings (P/E)35.7
Beta0.48
Next Earnings
Jan 22, 2025EPS Estimate
$1.34Last Dividend Ex-Date
Oct 15, 2024Dividend Yield1.9%
Share Statistics
EPS (TTM)3.29
Shares Outstanding1,734,455,213
10 Day Avg. Volume5,252,298
30 Day Avg. Volume4,956,578
Standard Deviation0.06
R-Squared0.39
Alpha-0.00033
Financial Highlights & Ratios
Price to Book (P/B)5.05
Price to Sales (P/S)4.93
Price to Cash Flow (P/CF)18.80
P/FCF Ratio23.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.11
Enterprise Value/Gross Profit9.52
Enterprise Value/Ebitda19.92
Forecast
1Y Price Target
$133.33Price Target Upside13.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
Abbott Laboratories News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceRevenue and EPS beat the Street's forecasts, with organic sales growth for the base business at 8.2% and Med Devices showing 13.3% growth.
Litigation OutcomeA St. Louis jury found that Abbott Labs and Reckitt Benckiser's Mead Johnson unit were not liable in the latest infant formula necrotizing enterocolitis lawsuit.
Product GrowthIn Diabetes Care, CGM sales showed 20.7% organic sales growth, overcoming previous concerns about supply constraints.
Bears Say
Financial PerformanceThe company's operating margin and core EPS, excluding COVID testing, were slightly below Street estimates, raising concerns about financial performance.
LitigationOngoing NEC litigation could remain an overhang on the stock due to additional state cases being tried and the potential for significant awards for Plaintiffs.
Sales GrowthQ3 organic sales growth of 8.2% missed the estimate of 9.2%, primarily due to issues in nutrition and diagnostics, which could signal underlying challenges.
---
Ownership Overview
0.48% Insiders
24.34% Mutual Funds
21.07% Other Institutional Investors
34.23% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ABT FAQ
What was Abbott Laboratories’s price range in the past 12 months?
Abbott Laboratories lowest stock price was $99.71 and its highest was $121.64 in the past 12 months.
What is Abbott Laboratories’s market cap?
Currently, no data Available
When is Abbott Laboratories’s upcoming earnings report date?
Abbott Laboratories’s upcoming earnings report date is Jan 22, 2025 which is in 61 days.
How were Abbott Laboratories’s earnings last quarter?
Abbott Laboratories released its earnings results on Oct 16, 2024. The company reported $1.21 earnings per share for the quarter, beating the consensus estimate of $1.202 by $0.008.
Is Abbott Laboratories overvalued?
According to Wall Street analysts Abbott Laboratories’s price is currently Undervalued.
Does Abbott Laboratories pay dividends?
Abbott Laboratories pays a Quarterly dividend of $0.55 which represents an annual dividend yield of 1.9%. See more information on Abbott Laboratories dividends here
What is Abbott Laboratories’s EPS estimate?
Abbott Laboratories’s EPS estimate is $1.34.
How many shares outstanding does Abbott Laboratories have?
Abbott Laboratories has 1,734,455,200 shares outstanding.
What happened to Abbott Laboratories’s price movement after its last earnings report?
Abbott Laboratories reported an EPS of $1.21 in its last earnings report, beating expectations of $1.202. Following the earnings report the stock price went up 1.525%.
Which hedge fund is a major shareholder of Abbott Laboratories?
Among the largest hedge funds holding Abbott Laboratories’s share is Fisher Asset Management LLC. It holds Abbott Laboratories’s shares valued at 1B.
---
Abbott Laboratories Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$133.33 (13.90% Upside)
$133.33 (13.90% Upside)
Blogger Sentiment
Bullish
ABT Sentiment 96%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 85.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $34.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.1%
Last 30 Days ▲ 11.4%
Last 30 Days ▲ 11.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
17.35%
12-Months-Change
Fundamentals
Return on Equity
14.87%
Trailing 12-Months
Asset Growth
3.14%
Trailing 12-Months
Company Description
Abbott Laboratories
Abbott Laboratories offers a diversified line of healthcare products. It operates through four reportable segments: Established Pharmaceutical Products International (includes international sales of branded generic pharmaceutical products), Nutritional Products Diagnostic Products and Medical Devices. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.
---
ABT Company Deck
---
ABT Earnings Call
Q3 2024
0:00 / 0:00
---
ABT Net sales Breakdown
42.10% Medical Devices
24.90% Diagnostic Products
20.33% Nutritional Products
12.63% Established Pharmaceutical Products
0.03% Other
---
ABT Stock 12 Month Forecast
Average Price Target
$133.33
▲(13.90% Upside)
Technical Analysis
Best Analysts Covering ABT
1 Year
1 Year Success Rate
24/26 ratings generated profit
1 Year Average Return
+19.95%
reiterated a buy rating last month
Copying Rick Wise's trades and holding each position for 1 Year would result in 92.31% of your transactions generating a profit, with an average return of +19.95% per trade.
---